I was never fully able to find an answer to this, but I came up with this: 1. Cash is tight (they appear to have an issues with a round of financing). Not many takers? 2. Something going on with System Sales in the asian region (not the consumables). 3. Slower than anticipated growth (which could indicate a stall)? Personally, I think they will get bought for about $6-7/share by some big pharma in the aesthetics space.